Geparin-Novofarm 5000 IU 5 ml. vial №5


Manufacturer: Ukraine

Treatment of diseases of the superficial veins, such as varicose veins, and related complications, phlebothrombosis, thrombophlebitis, and superficial periflebitis. Postoperative varicose phlebitis, complications after surgical removal of the saphenous vein of the leg. Injuries and bruises, infiltrates and localized edema, subcutaneous hematomas. Injuries and sprains of muscle-tendon and capsule-connected structures.



Geparin-Novofarm Storage
active substance: sodium heparin;

1 ml of solution contains 5000 IU of sodium heparin;

Excipients: benzyl alcohol, sodium chloride, water for injections.

Geparin-Novofarm Dosage form
Solution for injection.

Main physical and chemical properties: clear colorless or light yellow liquid without foreign particles.

Geparin-Novofarm Pharmacotherapeutic group
Antithrombotic drugs. Heparin group.

ATX code B01A B01.

Pharmacological properties


Heparin is a glycosaminoglycan (mucopolysaccharide), which consists of sulfated residues of D-glucosamine and D-glucuronic acid.

Heparin is a direct-acting anticoagulant. Heparin has a negative charge in the solution, which promotes its interaction with proteins involved in the process of blood clotting. Heparin binds to antithrombin III (heparin cofactor) and inhibits the process of blood clotting by inactivating factors V, VII, IX, X. This neutralizes the factors that activate blood clotting (kallikrein, IXa, Xa, Xia, XIIa), the transition is disturbed prothrombin to thrombin. Once the thrombosis process has begun, large amounts of heparin can inhibit further coagulation by inactivating thrombin and inhibiting the conversion of fibrinogen to fibrin. Heparin also prevents the formation of stable fibrin clots by inhibiting the activation of fibrin stabilizing factor. When administered parenterally, heparin slows blood clotting, activates the process of fibrinolysis, inhibits the activity of some enzymes (hyaluronidase, phosphatase, trypsin), slowing the effect of prostacyclin on platelet aggregation caused by adenosine diphosphate.


After intravenous infusion, the maximum level in blood plasma is reached in a few minutes, after a slow intravenous infusion – no later than 2-3 minutes, after subcutaneous injection – in 40-60 minutes. The volume of distribution of heparin corresponds to the volume of blood plasma and increases significantly with increasing dose of the drug. Plasma proteins at a heparin concentration of 2 IU / ml of blood bind up to 95% of the drug, at higher concentrations – less. Heparin is partially metabolized in the liver. About 20% is found in the urine in the form of unchanged heparin and uroheparin (has an activity of 50% of the active substance). The biological half-life is 1.32-1.72 hours. The half-life from blood plasma is 30-60 minutes In hepatic insufficiency, heparin accumulates. Heparin does not penetrate into breast milk, poorly penetrates the placenta.


Prevention and treatment of thromboembolic diseases and their complications (acute coronary syndrome, thrombosis and embolism of the main veins and arteries, cerebral vessels, eyes, phase I of the syndrome of disseminated intravascular coagulation, constant form of atrial fibrillation with embolization);
to prevent postoperative venous thrombosis and pulmonary embolism (low-dose) in patients who have undergone surgery or in those who, for any other reason, are at risk of developing thromboembolic disease;
to prevent blood clotting in laboratory tests, dialysis, extracorporeal circulation, operations on the heart and blood vessels, direct blood transfusion.

Hypersensitivity to heparin and / or to benzyl alcohol; hemophilia; hemorrhagic diathesis; thrombocytopenia; suspected heparin-induced immune thrombocytopenia; peptic ulcer of the stomach and duodenum; severe hypertension; cirrhosis of the liver, accompanied by varicose veins of the esophagus; severe renal and hepatic failure; bacterial endocarditis; menstruation; recent surgeries, especially neurosurgical and ophthalmic; ulcerative colitis; malignant neoplasms; hemorrhagic stroke (first 2-3 days); craniocerebral injuries; retinopathy; hemorrhage in the eye tissue; destructive pulmonary tuberculosis; encephalomyelitis; hemorrhagic pancreatic necrosis; bleeding of any localization (open gastric ulcer, intracranial hemorrhage), except for hemorrhage caused by embolic heart attack (hemoptysis) or kidney (hematuria); recurrent bleeding in the anamnesis, regardless of location; increased vascular permeability (for example, in Werlhof’s disease); state of shock; threat of abortion.